Fathom Holdings Inc

Bed Bath & Beyond stock soared after Wedbush Securities upgraded the retailer to Outperform with an $11 price target, implying over 65% upside. Analyst Seth Basham cited the company's 2026 transformation, including an all-stock merger with Fathom Holdings and the acquisition of F9 Brand assets like LL Flooring, positioning it as an end-to-end homeownership platform. Trading at about 0.41 times sales, the stock reflects a disconnect from its revenue potential, while Q1 revenue rose 6.9% year-on-year to $248 million, breaking a 19-quarter streak of declines. The consensus rating on Bed Bath & Beyond is Moderate Buy with a mean price target of $9.75.

Brodsky & Smith is investigating the boards of Arcosa, Fathom Holdings, Nuvalent, and Dana Incorporated over potential fiduciary duty breaches in their respective merger agreements. Arcosa is being acquired by CRH for $150.00 per share in cash, with a total enterprise value of approximately $8.5 billion. Fathom Holdings is being acquired by Bed Bath & Beyond in a deal implying an equity value of about $53.38 million, with an exchange ratio of 0.2236 Bed Bath & Beyond shares per Fathom share. Nuvalent is being acquired by GSK for $124.00 per share in cash in a deal valued at $10.6 billion. Dana is being acquired by Eaton Corporation in a transaction valued at approximately $5.1 billion, where Eaton shareholders will own at least 50.1% and Dana shareholders approximately 49.9% of the combined company, and Eaton will receive a cash distribution of about $1.1 billion.